Akari Therapeutics, Plc
AKTX · NASDAQ
Market closed$11.01$-0.490000 (-4.26%)After hours $11.01 · 0.00%
Key statistics
Previous close$11.50
Open$11.18
Day high$11.64
Day low$10.70
52-week high$49.60
52-week low$3.02
Market cap12.60M
Volume42.19K
Average volume804.18K
P/E ratio-2.46
Forward P/E—
EPS-4.48
Dividend yield0.00%
Market context
Why it moved
AKTX shares declined amid a lack of positive catalysts and persistent selling pressure, as the stock continued to pull back from recent highs despite analyst price targets remaining significantly above current trading levels.
What is happening
Recent company-specific developments and publisher coverage.
Barchart.com · July 14, 2026Akari Therapeutics (AKTX) Is Advancing the Next Generation of Antibody Drug Conjugates Through Novel Payload InnovationGlobeNewswire · July 7, 2026Akari Therapeutics Appoints Former AACR President andQuiver Quantitative · June 29, 2026Akari Therapeutics Completes Consolidated PIPE Closing, Receives $8.3 Million in Total Q2 2026 CapitalBenzinga · May 26, 2026Why Akari Therapeutics Stock Is Falling On Tuesday?GuruFocus · May 22, 2026Akari Therapeutics (AKTX) Shares Surge 120% on Promising Preclinical Cancer Therapy DataSeeking Alpha · May 22, 2026Akari Therapeutics gains on positive preclinical data for cancer therapy (AKTX:NASDAQ)Quiver Quantitative · May 22, 2026Akari Therapeutics (AKTX) surges as new KRAS pancreatic cancer data and a $5.5M financing grab investor attentionInvesting.com · May 21, 2026Akari Therapeutics stock rockets 50% higher on KRAS combination data Benzinga · July 2, 2026Akari Therapeutics Files Prospectus Related To Resale Of Up To 6M ADSs Representing 480B Ordinary Shares By The Selling Shareholders Benzinga · May 28, 2026Akari Therapeutics CEO Highlights ASCO Data Demonstrating Synergy Of AKTX-101 With Adagasrib In KRAS-Driven Cancers In Virtual Investor "What This Means" Segment Benzinga · May 26, 2026Why Akari Therapeutics Stock Is Falling On Tuesday? Benzinga · May 22, 2026Akari Therapeutics Stock Jumps On Promising Preclinical Data Benzinga · May 21, 2026Akari Therapeutics' AKTX-101 Shows Synergistic Preclinical Cytotoxicity With KRAS Inhibitor In KRAS-Mutant Pancreatic Cancer Models, Highlighting RNA Splicing Payload Advantage Benzinga · May 21, 2026Akari Therapeutics Commences $5.5M Private Placement Benzinga · May 14, 2026Why Akari Therapeutics Stock Is Surging On Thursday? Benzinga · May 12, 2026Akari Therapeutics Granted European Patent For Proprietary ADC Payload Platform Technology